Effect of vigabatrin on the pharmacokinetics of carbamazepine

@article{SnchezAlcaraz2002EffectOV,
  title={Effect of vigabatrin on the pharmacokinetics of carbamazepine},
  author={Agust{\'i}n S{\'a}nchez-Alcaraz and M B Quintana and E L{\'o}pez and I Rodr{\'i}guez and Paloma Albaladejo Llopis},
  journal={Journal of Clinical Pharmacy and Therapeutics},
  year={2002},
  volume={27}
}
Objective:  To evaluate a possible interaction between vigabatrin and carbamazepine in epileptic patients. 
Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents.
  • B. Steinborn
  • Medicine
  • Roczniki Akademii Medycznej w Bialymstoku
  • 2005
TLDR
Pharmacokinetic interactions of CBZ with LTG, TPM, VGB or VPA in children are associated only with the changes in total CBZ parameters. Expand
Effects of vigabatrin, carbamazepine or its combination on the pituitarygonadal axis in male Wistar rats
TLDR
Significant decrease in the levels of luteinizing hormone, follicle stimulating hormone, testosterone and sperm physiological indices were showed and there was restoration of these parameters sequelae to 8 weeks cessation of treatment. Expand
Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval
TLDR
The recent approval of vigabatrin makes a significant addition to antiepileptic drug options. Expand
Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 1: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs
TLDR
Overall, the new AEDs are less interacting primarily because many are renally excreted or not hepatically metabolised and most do not (or minimally) induce or inhibit hepatic metabolism. Expand
Chapter 7 – Vigabatrin
Publisher Summary The chapter presents a general description of the drug Vigabatrin that is used as an adjunctive antiepileptic in patients with resistant partial epilepsy with or without secondaryExpand
New Antiepileptic Drugs: Lacosamide, Rufinamide, and Vigabatrin
TLDR
The three newest antiepileptic medications (lacosamide, rufinamide, and vigabatrin) all putatively have novel mechanisms of action, which might increase the chance of treatment success in patients failing previous antIEpilepsy drug trials and the chances of successful synergy with currently available medications. Expand
Pharmacokinetic aspects of the anti-epileptic drug substance vigabatrin: focus on transporter interactions.
TLDR
The transporter(s) involved in the intestinal absorption of vigabatrin in vitro and in vivo are discussed in detail and special focus is on the contribution of the proton-coupled amino acid transporter 1 (PAT1) for intestinal vigab atrin absorption. Expand
Therapeutic Drug Monitoring of Carbamazepine
TLDR
Review is mostly centred on toxic effects, poorly adjusted therapies and poor seizure control, and individualization of drug dose with the help of plasma level detection is a must in case of Carbamazepine therapy. Expand
Epilepsy New Antiepileptic Drugs : Lacosamide , Rufinamide , and Vigabatrin
The treatment of epilepsy is complicated by the multiple seizure types and epilepsy syndromes needing therapy. In addition, seizures in up to 30% of epilepsy patients are resistant to availableExpand
The Impact of Anti-Epileptic Drugs on Growth and Bone Metabolism
TLDR
The need for caution and timely withdrawal of these medications to avoid serious disabilities is emphasized and the impact of AEDs on growth and bone metabolism is focused on. Expand
...
1
2
...

References

SHOWING 1-10 OF 10 REFERENCES
Plasma concentrations of vigabatrin in epileptic patients
Objective: To measure plasma concentrations of vigabatrin in a group of 30 adult epileptic patients with complex partial seizures (CPS) refractory to conventional antiepileptic drugs. With a view toExpand
Interaction between vigabatrin and phenytoin.
TLDR
Although an interaction between phenytoin and vigabatrin has been confirmed, the mechanism has not been elucidated and the mechanisms behind the fall in plasma pheny toin concentrations are still unknown. Expand
Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.
TLDR
It is concluded that the oral availability of PHT is unaffected by VGB and that the VBG-induced decrease in serum P HT is mediated by alternative mechanisms. Expand
Vigabatrin. Clinical pharmacokinetics.
TLDR
Monitoring of plasma concentrations of vigabatrin as a guide to dosage is unlikely to be of as much value as with other antiepileptic drugs, because the action of the drug long outlasts its presence in plasma. Expand
Rationalized polytherapy for epilepsy
TLDR
Vigabatrin was not shown to have any harmful effects in extensive laboratory, EEG and cognitive function tests, and a minor improvement occurred in visual memory, which was probably related to the reduction in seizures. Expand
Pharmacological principles as a basis for polytherapy
  • E. Perucca
  • Medicine
  • Acta neurologica Scandinavica. Supplementum
  • 1995
TLDR
Preliminary observations do suggest that, in some cases, the efficacy exhibited by certain new drugs could be explained in terms of their pharmacological effect being‘complementary’ to that of concurrently used agents. Expand
Monotherapy or Poly therapy for Epilepsy?
Summary: Although anticonvulsant polytherapy has been widely and traditionally used in the treatment of epilepsy, there is little evidence of its advantages over monotherapy. It does, however, leadExpand
Neuropsychological deficit in newly diagnosed patients with schizophrenia or schizophreniform disorder
TLDR
Patients with schizophrenia or schizophreniform disorder admitted to hospital for the first time were compared with healthy volunteers on neuropsychological tests reflecting prefrontal and left respectively right hemisphere function, indicating dysfunction of prefrontal and temporohippocampal regions. Expand
Influence of vigabatrin on the pharmacokinetic parameters of valproic acid
  • European Hospital Pharmacy (E.H.P.),
  • 1996
Influence of vigabatrin on the pharmacokinetic parameters of valproic acid. European Hospital Pharmacy
  • 1996